The Indian government has proposed tighter restrictions on advertisements for prescription medicines, aiming to strengthen oversight across the pharmaceutical supply chain. The draft amendment would extend advertising restrictions to retailers, wholesalers and distributors, with GLP-1 weight-loss medicines among the products drawing regulatory attention.
1. What Does the Government’s Proposal Say?
The Union Ministry of Health and Family Welfare has proposed changes to the Drugs Rules, 1945. The amendment seeks to require prior Central Government approval for advertisements of medicines listed under Schedules H, H1 and X, extending the restriction to businesses involved in selling and distributing these drugs.
2. Why Are GLP-1 Medicines in Focus?
GLP-1 receptor agonists are medicines used to manage type 2 diabetes and, for certain approved products and indications, weight management. Growing demand has raised concerns about inappropriate use, unauthorised sales and marketing that may encourage people to seek these medicines without suitable medical supervision.
3. Closing a Gap in Advertising Rules
Under the existing framework described in the draft, restrictions apply to pharmaceutical manufacturers, but the rules do not explicitly extend the same prior-approval requirement to every retailer and wholesaler. The proposed amendment aims to address this gap by bringing more participants in the drug supply chain under the advertising restrictions.
4. Surrogate Advertising Under Scrutiny
Regulators are also concerned about indirect promotion through influencer collaborations, online campaigns and disease-awareness initiatives that may create demand for specific prescription medicines. In March 2026, the Central Drugs Standard Control Organisation (CDSCO) issued an advisory warning against direct and surrogate promotion of GLP-1 medicines to the public.
5. Earlier Steps to Strengthen Oversight
The latest proposal follows other regulatory measures targeting the promotion and sale of prescription medicines. In March, authorities intensified surveillance of the GLP-1 supply chain, with inspections of 49 entities, including pharmacies, wholesalers, online pharmacy warehouses and weight-management clinics.
6. What Could Change for Pharmacies and Distributors?
If the amendment is finalised, pharmacies, wholesalers and distributors may need to review their advertising and promotional practices to ensure compliance. The proposal could also reinforce scrutiny of digital promotions and marketing campaigns that indirectly encourage the use of prescription-only medicines.
7. The Proposal Is Not Yet Final
The Ministry has invited objections and suggestions from stakeholders and members of the public within 30 days of the draft notification being made available. Submissions will be considered before the amendment is finalised.
The proposal reflects a broader effort to strengthen safeguards around prescription medicines and discourage inappropriate self medication. Until the draft is finalised, however, the proposed changes should not be treated as a new rule already in force.